Distinguished in Endometrial Stromal Sarcoma

Philipp N. Harter

Kliniken Essen Mitte
Essen, NW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Endometrial Stromal Sarcoma
Kliniken Essen Mitte
Essen, NW, DE 
OverviewLocationsClinical Research

Overview

Philipp Harter practices in Essen, Germany. Mr. Harter is rated as a Distinguished expert by MediFind in the treatment of Endometrial Stromal Sarcoma. His top areas of expertise are Ovarian Cancer, Vulvar Cancer, Endometrial Cancer, Lymphadenectomy, and Vulvectomy.

His clinical research consists of co-authoring 322 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Endometrial Stromal Sarcoma.

Gender
Male

Locations

Kliniken Essen Mitte
Essen, NW 45136, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Pelvic and Para-aortic Lymphadenectomy in Patients With Stage I or II Endometrial Cancer With High Risk of Recurrence
Pelvic and Para-aortic Lymphadenectomy in Patients With Stage I or II Endometrial Cancer With High Risk of Recurrence
Enrollment Status: Recruiting
Publish Date: November 25, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
Phase II Investigational Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Phase II Investigational Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 3
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
View 3 Less Clinical Trials

322 Total Publications

Cytoreductive surgery for recurrent platinum-sensitive low-grade ovarian carcinoma: a retrospective single institution experience.
Cytoreductive surgery for recurrent platinum-sensitive low-grade ovarian carcinoma: a retrospective single institution experience.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: July 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Harter's expertise for a condition
ConditionClose
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile